Sputnik Light vaccine approved for use in Palestine

Sputnik Light vaccine approved for use in Palestine

RDIF, Russia’s sovereign wealth fund announces the approval of the Russian single-dose Sputnik Light vaccine against coronavirus by the Ministry of Health of the State of Palestine

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V. Sputnik Light demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered.

The data was obtained from Russians vaccinated with a single injection, having not received the second one for any reason during the mass vaccination program between December 5, 2020 and April 15, 2021. An efficacy level of near 80% is higher than that of many two-dose vaccines.

In January 2021, the two-dose Sputnik V vaccine was also approved for use in Palestine under the emergency use authorization procedure.

To date Sputnik V has been authorized in 66 countries with total population of over 3.2 billion people.

Kirill Dmitriev
Kirill Dmitriev
CEO of the Russian Direct Investment Fund
Using the single-dose Sputnik Light vaccine significantly reduces the possibility of severe cases leading to hospitalization. Thanks to Sputnik Light authorities in Palestine will be able to immunize large groups in a shorter time achieving herd immunity faster.

SlidemegglemegglemegglemegglemegglemeggleEXPERTS IN EXCIPIENTS

Search engine for pharmaceutical industry resources

Type in a search phrase such as - gmp and get the search result

Don’t miss your daily PharmaProm.Ru news.
SUBSCRIBE free here

SUBSCRIBE
Loading…